版本:
中国

BRIEF-Innocoll announces regulatory path forward

March 29 Innocoll Holdings Plc:

* Innocoll announces regulatory path forward after receiving formal FDA type a meeting minutes regarding its xaracoll (bupivacaine HCL collagen-matrix implant) new drug application

* Innocoll Holdings - announced receipt of formal type a meeting minutes from FDA relating to its new drug application (NDA) for xaracoll

* Innocoll Holdings-believes, if adequately financed, successful, additional studies may be completed in time for a NDA resubmission for xaracoll at end of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐